Intervention not reported
Withdrawals due to adverse effects 5 years · Adults with mild hypertension and no cardiovascular disease
The intervention probably leads to higher withdrawals due to adverse effects 5 years (moderate certainty).
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse effects at end of treatment · adults with tinnitus
CBT showed no clear difference in serious adverse effects at end of treatment compared with no intervention/waiting list control (moderate certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Gastrointestinal adverse events · chronic rhinosinusitis
Systemic antifungal showed no clear difference in adverse effects ‐ gastrointestinal disturbances compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 0.37 [0.04, 3.36]
Studies not reported
Low
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with severe delirium
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes adverse events including extrapyramidal effectsd compared with placebo plus haloperidol (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with chlorpromazine (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with lorazepam (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in adverse events including extrapyramidal effectse compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · hyperuricaemia in people with hypertension
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
1 finding from 1 review
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Ciprofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with ciprofloxacin (moderate certainty).
1 finding from 1 review